Search Results - "RUTHERFORD, Thomas J"

A phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who carry a germline BRCA1 or BRCA2 mutation — An NRG Oncology/Gynecologic Oncology Group study by Coleman, Robert L, Sill, Michael W, Bell-McGuinn, Katherine, Aghajanian, Carol, Gray, Heidi J, Tewari, Krishnansu S, Rubin, Steven C, Rutherford, Thomas J, Chan, John K, Chen, Alice, Swisher, Elizabeth M

“…Abstract Background Veliparib is a potent small molecule inhibitor of PARP-1/2, which is cytotoxic in tumor cells with deficiencies in BRCA1 or BRCA2 . We…”
Get full text

Landscape of somatic single-nucleotide and copy-number mutations in uterine serous carcinoma by Zhao, Siming, Choi, Murim, Overton, John D., Bellone, Stefania, Roque, Dana M., Cocco, Emiliano, Guzzo, Federica, English, Diana P., Varughese, Joyce, Gasparrini, Sara, Bortolomai, Ileana, Buza, Natalia, Hui, Pei, Abu-Khalaf, Maysa, Ravaggi, Antonella, Bignotti, Eliana, Bandiera, Elisabetta, Romani, Chiara, Todeschini, Paola, Tassi, Renata, Zanotti, Laura, Carrara, Luisa, Pecorelli, Sergio, Silasi, Dan-Arin, Ratner, Elena, Azodi, Masoud, Schwartz, Peter E., Rutherford, Thomas J., Stiegler, Amy L., Mane, Shrikant, Boggon, Titus J., Schlessinger, Joseph, Lifton, Richard P., Santin, Alessandro D.

“…Uterine serous carcinoma (USC) is a biologically aggressive subtype of endometrial cancer. We analyzed the mutational landscape of USC by whole-exome…”
Get full text

Microscopic Omental Metastasis in Clinical Stage I Endometrial Cancer: A Meta-analysis by Joo, Won Duk, Schwartz, Peter E., Rutherford, Thomas J., Seong, Seok Ju, Ku, Junbeom, Park, Hyun, Jung, Sang Geun, Choi, Min Chul, Lee, Chan

“…Background A patient with early-stage endometrial cancer may possibly have microscopic metastasis in the omentum, which is associated with a poor prognosis…”
Get full text

Eradication of chemotherapy‐resistant CD44+ human ovarian cancer stem cells in mice by intraperitoneal administration of clostridium perfringens enterotoxin by Casagrande, Francesca, Cocco, Emiliano, Bellone, Stefania, Richter, Christine E., Bellone, Marta, Todeschini, Paola, Siegel, Eric, Varughese, Joyce, Arin‐Silasi, Dan, Azodi, Masoud, Rutherford, Thomas J., Pecorelli, Sergio, Schwartz, Peter E., Santin, Alessandro D.

“…BACKGROUND: Emerging evidence has suggested that the capability to sustain tumor formation, growth, and chemotherapy resistance in ovarian as well as other…”
Get full text

Proteomic studies of VEGFR2 in human placentas reveal protein associations with preeclampsia, diabetes, gravidity, and labor by Ho, Shannon J, Chaput, Dale, Sinkey, Rachel G, Garces, Amanda H, New, Erika P, Okuka, Maja, Sang, Peng, Arlier, Sefa, Semerci, Nihan, Steffensen, Thora S, Rutherford, Thomas J, Alsina, Angel E, Cai, Jianfeng, Anderson, Matthew L, Magness, Ronald R, Uversky, Vladimir N, Cummings, Derek A T, Tsibris, John C M

“…VEGFR2 (Vascular endothelial growth factor receptor 2) is a central regulator of placental angiogenesis. The study of the VEGFR2 proteome of chorionic villi at…”
Get full text

Neratinib shows efficacy in the treatment of HER2/neu amplified uterine serous carcinoma in vitro and in vivo by Schwab, Carlton L, English, Diana P, Roque, Dana M, Bellone, Stefania, Lopez, Salvatore, Cocco, Emiliano, Nicoletti, Roberta, Rutherford, Thomas J, Schwartz, Peter E, Santin, Alessandro D

“…Abstract Objectives Uterine serous carcinoma (USC) represents an aggressive variant of endometrial cancer and accounts for a large proportion of deaths…”
Get full text

Qualitative assessment of knowledge and attitudes towards cervical cancer screening among male Latino immigrants in Houston, Texas by Read, Susan H, Valverde, Ivan, Montealegre, Jane R, Rutherford, Thomas J, Anderson, Matthew L

“…Background Male spouses and partners play an important role in determining a woman's willingness to participate in cervical cancer screening. However, the…”
Get full text

Clostridium perfringens enterotoxin C‐terminal domain labeled to fluorescent dyes for in vivo visualization of micrometastatic chemotherapy‐resistant ovarian cancer by Cocco, Emiliano, Shapiro, Erik M., Gasparrini, Sara, Lopez, Salvatore, Schwab, Carlton L., Bellone, Stefania, Bortolomai, Ileana, Sumi, Natalia J., Bonazzoli, Elena, Nicoletti, Roberta, Deng, Yang, Saltzman, W. Mark, Zeiss, Caroline J., Centritto, Floriana, Black, Jonathan D., Silasi, Dan‐Arin, Ratner, Elena, Azodi, Masoud, Rutherford, Thomas J., Schwartz, Peter E., Pecorelli, Sergio, Santin, Alessandro D.

“…Identification of micrometastatic disease at the time of surgery remains extremely challenging in ovarian cancer patients. We used fluorescence microscopy, an…”
Get full text

ERCC1 Genotype and Phenotype in Epithelial Ovarian Cancer Identify Patients Likely to Benefit From Paclitaxel Treatment in Addition to Platinum-Based Therapy by SMITH, Stephanie, DAN SU, RIGAULT DE LA LONGRAIS, Irene A, SCHWARTZ, Peter, PUOPOLO, Manuela, RUTHERFORD, Thomas J, MOR, Gil, YU, Herbert, KATSAROS, Dionyssios

“…To investigate the effect of excision repair cross-complementation group 1 (ERCC1) on treatment response and survival of patients treated with platinum…”
Get full text

Oxidized Regenerated Cellulose Mimicking a Retained Laparotomy Sponge by Karnolt, Lauren E., Buras, Andrea L., Rutherford, Thomas J., Anderson, Matthew L.

“…Oxidized regenerated cellulose (ORC) is an absorbable hemostat commonly used during gynecologic surgery. We present a case in which ORC was used in a patient…”
Get full text

Feasibility and safety of planned early discharge following laparotomy in gynecologic oncology with enhanced recovery protocol including opioid-sparing anesthesia by Kuznicki, Michelle L, Yasukawa, Maya, Mallen, Adrianne R, Lam, Clarissa, Eggers, Erica, Regis, Jefferson, Wells, Ali, Todd, Sarah L, Robertson, Sharon E, Tanner, Jean-Paul, Anderson, Matthew L, Rutherford, Thomas J

“…This study aims to evaluate the feasibility and safety of planned postoperative day 1 discharge (PPOD1) among patients who undergo laparotomy (XL) in the…”
Get full text

Cervical carcinomas overexpress human trophoblast cell-surface marker (Trop-2) and are highly sensitive to immunotherapy with hRS7, a humanized monoclonal anti-Trop-2 antibody by Varughese, Joyce, MD, Cocco, Emiliano, PhD, Bellone, Stefania, PhD, Ratner, Elena, MD, Silasi, Dan-Arin, MD, Azodi, Masoud, MD, Schwartz, Peter E., MD, Rutherford, Thomas J., MD, PhD, Buza, Natalia, MD, Pecorelli, Sergio, MD, PhD, Santin, Alessandro D., MD

“…Objective We evaluated the expression of human trophoblast cell-surface marker (Trop-2) and the potential of hRS7, a humanized monoclonal anti-Trop-2 antibody,…”
Get full text

Human Papillomavirus Type 16 (HPV-16) Virus-Like Particle L1-Specific CD8+ Cytotoxic T Lymphocytes (CTLs) Are Equally Effective as E7-Specific CD8+ CTLs in Killing Autologous HPV-16-Positive Tumor Cells in Cervical Cancer Patients: Implications for L1 Dendritic Cell-Based Therapeutic Vaccines by BELLONE, Stefania, EL-SAHWI, Karim, SCHWARTZ, Peter E, RUTHERFORD, Thomas J, PECORELLI, Sergio, SANTIN, Alessandro D, COCCO, Emiliano, CASAGRANDE, Francesca, CARGNELUTTI, Marilisa, PALMIERI, Michela, BIGNOTTI, Eliana, ROMANI, Chiara, SILASI, Dan-Arin, AZODI, Masoud

“…Article Usage Stats Services JVI Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley…”
Get full text

Clostridium perfringens enterotoxin carboxy-terminal fragment is a novel tumor-homing peptide for human ovarian cancer by Cocco, Emiliano, Casagrande, Francesca, Bellone, Stefania, Richter, Christine E, Bellone, Marta, Todeschini, Paola, Holmberg, Jennie C, Fu, Han Hsuan, Montagna, Michele K, Mor, Gil, Schwartz, Peter E, Arin-Silasi, Dan, Azoudi, Masoud, Rutherford, Thomas J, Abu-Khalaf, Maysa, Pecorelli, Sergio, Santin, Alessandro D

“…Development of innovative, effective therapies against recurrent/chemotherapy-resistant ovarian cancer remains a high priority. Using high-throughput…”
Get full text

A survey of gynecologic oncologists regarding the End-of-Life discussion: A pilot study by El-Sahwi, Karim S, Illuzzi, Jessica, Varughese, Joyce, Carusillo, Nina, Ratner, Elena S, Silasi, Dan-Arin, Azodi, Masoud, Schwartz, Peter E, Rutherford, Thomas J, Santin, Alessandro D

“…Abstract Objectives. To identify the practices and attitudes of gynecologic oncologists regarding the end-of-life discussion. Methods. A pilot survey was sent…”
Get full text

HER-2/NEU overexpression in vulvar Paget disease: the Yale experience by Richter, Christine E, Hui, Pei, Buza, Natalia, Silasi, Dan-Arin, Azodi, Masoud, Santin, Alessandro D, Schwartz, Peter E, Rutherford, Thomas J

“…To determine the level of HER-2/neu overexpression in vulvar Paget disease (PD) in order to assess the possibility of using HER-2/neu as a target for the…”
Get more information

High-grade, chemotherapy-resistant ovarian carcinomas overexpress epithelial cell adhesion molecule (EpCAM) and are highly sensitive to immunotherapy with MT201, a fully human monoclonal anti-EpCAM antibody by Richter, Christine E., MD, Cocco, Emiliano, PhD, Bellone, Stefania, PhD, Silasi, Dan-Arin, MD, Rüttinger, Dominik, MD, PhD, Azodi, Masoud, MD, Schwartz, Peter E., MD, Rutherford, Thomas J., MD, Pecorelli, Sergio, MD, Santin, Alessandro D., MD

“…Objective We evaluated the expression of epithelial cell adhesion molecule (EpCAM) and the potential of MT201 (adecatumumab), a human-monoclonal-antibody that…”
Get full text

Expression of tissue factor in adenocarcinoma and squamous cell carcinoma of the uterine cervix: implications for immunotherapy with hI-con1, a factor VII-IgGFc chimeric protein targeting tissue factor by Cocco, Emiliano, Varughese, Joyce, Buza, Natalia, Bellone, Stefania, Glasgow, Michelle, Bellone, Marta, Todeschini, Paola, Carrara, Luisa, Silasi, Dan-Arin, Azodi, Masoud, Schwartz, Peter E, Rutherford, Thomas J, Pecorelli, Sergio, Lockwood, Charles J, Santin, Alessandro D

“…Cervical cancer continues to be an important worldwide health problem for women. Up to 35% of patients who are diagnosed with and appropriately treated for…”
Get full text

Overexpression of EpCAM in Uterine Serous Papillary Carcinoma: Implications for EpCAM-Specific Immunotherapy With Human Monoclonal Antibody Adecatumumab (MT201) by El-Sahwi, Karim, Bellone, Stefania, Cocco, Emiliano, Casagrande, Francesca, Bellone, Marta, Abu-Khalaf, Maysa, Buza, Natalia, Tavassoli, Fattaneh A., Hui, Pei, Rüttinger, Dominik, Silasi, Dan-Arin, Azodi, Masoud, Schwartz, Peter E., Rutherford, Thomas J., Pecorelli, Sergio, Santin, Alessandro D.

“…We evaluated the expression of epithelial cell adhesion molecule (EpCAM) and the potential of MT201 (adecatumumab), a human monoclonal antibody against EpCAM,…”
Get full text

Uterine and ovarian carcinosarcomas overexpressing Trop-2 are sensitive to hRS7, a humanized anti-Trop-2 antibody by Raji, Rhoda, Guzzo, Federica, Carrara, Luisa, Varughese, Joyce, Cocco, Emiliano, Bellone, Stefania, Betti, Marta, Todeschini, Paola, Gasparrini, Sara, Ratner, Elena, Silasi, Dan-Arin, Azodi, Masoud, Schwartz, Peter, Rutherford, Thomas J, Buza, Natalia, Pecorelli, Sergio, Santin, Alessandro D

“…We evaluated the expression of human trophoblastic cell-surface marker (Trop-2) and the potential of hRS7 - a humanized monoclonal anti-Trop-2 antibody - as a…”
Get full text